Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

Infinity Bio完成由Illumina Ventures领投的800万美元A轮融资，以扩大其在抗体反应组分析领域的领导地位。

Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc.

投资支持平台创新、商业扩展和新服务开发；Infinity收购了Serimmune, Inc.的资产。

BALTIMORE, June 18, 2025-- Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund..

巴尔的摩，2025年6月18日——Infinity Bio是一家开发生物技术以大规模绘制免疫反应图谱的生物技术公司，今天宣布成功完成了800万美元的A轮融资。本轮融资由Illumina Ventures领投，PTX Capital、Blackbird BioVentures和Propel Baltimore Fund参与投资。

As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSIGHT™, are also expected to launch in the second half of 2025..

作为其拓宽服务范围战略计划的一部分，Infinity Bio收购了Serimmune, Inc.的资产，该公司成立于2014年，旨在提供无偏见的抗体反应组服务。新的MIPSA™服务产品，包括EnviroSIGHT™，预计将在2025年下半年推出。

Infinity Bio will use the proceeds to expand its commercial footprint, accelerate development of its proprietary MIPSA™ platform, and launch new immune profiling services. The platform enables unbiased, high-resolution analysis of the antibody reactome, an emerging field critical to understanding immune responses in health and disease..

Infinity Bio将利用这笔资金扩大其商业版图，加速推进其专有的MIPSA™平台开发，并推出新的免疫分析服务。该平台能够对抗体反应组进行无偏见、高分辨率的分析，这一新兴领域对于理解健康和疾病中的免疫反应至关重要。

“This raise marks a major milestone for Infinity Bio,” said Joy Nassif, Chief Executive Officer of the company. “We are building the foundation for a new category of immune system intelligence: accessible, scalable, and deeply informative. With support from our investors, we can now move faster to deliver that vision.”.

“这次融资标志着Infinity Bio的一个重要里程碑，”公司首席执行官Joy Nassif表示。“我们正在为免疫系统情报的新类别奠定基础：可及、可扩展且信息丰富。在投资者的支持下，我们现在可以更快地实现这一愿景。”

Since its founding in 2023, Infinity Bio has built out a 9,000 square-foot laboratory in Baltimore and developed a suite of core services including HuSIGHT™, VirSIGHT™, AllerSIGHT™, and MuSIGHT™, designed to support applications in biomarker discovery, basic and translational research, and therapeutic development.

自2023年成立以来，Infinity Bio已在巴尔的摩建立了9,000平方英尺的实验室，并开发了一系列核心服务，包括HuSIGHT™、VirSIGHT™、AllerSIGHT™和MuSIGHT™，旨在支持生物标志物发现、基础与转化研究以及治疗开发等应用。

The company’s platform is capable of processing thousands of samples per week, serving academic, government, and biopharma customers..

该公司的平台每周能够处理数千个样本，为学术、政府和生物制药客户提供服务。

“True to our name, Infinity Bio is building a limitless capacity to generate high quality antibody reactome data and deliver valuable biological insights for just about any kind of study,” says Ben Larman, Chief Science Officer of Infinity Bio, and associate professor of pathology at Johns Hopkins University.

“正如我们的名字一样，Infinity Bio 正在构建无限的能力，以生成高质量的抗体反应组数据，并为几乎所有类型的研究提供有价值的生物学见解，”Infinity Bio 的首席科学官、约翰霍普金斯大学病理学副教授 Ben Larman 表示。

He adds, “our technologies illuminate the complex interplay between inflammation, immunity, and health.”.

他补充说：“我们的技术揭示了炎症、免疫和健康之间的复杂相互作用。”

“We applaud the scientific prowess of Infinity Bio to provide insights into the immune system through its antibody reactome profiling platform,” said Malek Faham, MD, PhD, Chief Scientist at Illumina Ventures. “Combined with the assets from Serimmune, this enhanced, more comprehensive technology is a game changer for biomedical researchers who can use it for a broad range of applications to accelerate their discoveries.”.

“我们赞扬Infinity Bio通过其抗体反应组分析平台提供对免疫系统见解的科学实力，”Illumina Ventures首席科学家Malek Faham博士表示，“结合Serimmune的资源，这项更强大、更全面的技术为生物医学研究人员带来了变革，他们可以将其用于广泛的应用以加速研究发现。”

“We launched Infinity Bio with global ambition to unlock a new layer of immune system data that drives better diagnostics, targeted therapies, and deeper disease insight,” said Matt Hellauer, Managing Partner at PTX Capital and Chairman of Infinity Bio. “Partnering with a world-class firm like Illumina Ventures reinforces that vision and positions Infinity to scale as the category leader in antibody reactome profiling.'.

“我们推出Infinity Bio，以全球视野解锁免疫系统数据的新层次，推动更精准的诊断、靶向治疗和更深入的疾病洞察，”PTX资本管理合伙人兼Infinity Bio董事长马特·赫拉尔表示。“与Illumina Ventures这样的世界级公司合作，强化了这一愿景，并使Infinity Bio有望成为抗体反应组分析领域的领军者。”

For more information, visit www.infinitybio.com.

欲了解更多信息，请访问 www.infinitybio.com。

About Infinity Bio

关于Infinity Bio

Infinity Bio, Inc. is a technology company that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform. The company's core technology, MIPSA, is used to comprehensively analyze the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and allergen proteins.

Infinity Bio, Inc. 是一家技术公司，利用其专有的抗体反应组分析平台提供对免疫系统的深入洞察。该公司的核心技术 MIPSA 用于全面分析抗体反应组，揭示针对所有已知人类病毒、人类蛋白（自身免疫）和过敏原蛋白的个体免疫反应目标。

Developed at Johns Hopkins University in The Laboratory of Precision Immunology, MIPSA builds on decades of work in genomics, proteomics, immunology, and bioinformatics. Infinity Bio's assays are engineered to enable best-in-class quality, data accuracy, turnaround times and cost-efficiency. For more information, visit www.infinitybio.com..

在约翰霍普金斯大学精准免疫学实验室开发的MIPSA，基于数十年在基因组学、蛋白质组学、免疫学和生物信息学领域的工作成果。Infinity Bio的检测方法旨在实现一流的品质、数据准确性、周转时间和成本效益。欲了解更多信息，请访问www.infinitybio.com。

About Illumina Ventures

关于Illumina Ventures

Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN). As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare.

Illumina Ventures 是一家与 Illumina（纳斯达克股票代码：ILMN）建立战略合作伙伴关系的独立管理、专注于医疗保健的风险投资公司。作为早期的价值增值投资者，Illumina Ventures 帮助企业家将突破性的科学和技术发展为市场领先的公司，以变革医疗保健行业。

The firm focuses on investment in life science tools, therapeutics, diagnostics, personal wellness, and sustainability. To learn more, visit illuminaventures.com..

该公司专注于生命科学工具、治疗学、诊断学、个人健康和可持续性的投资。欲了解更多信息，请访问 illuminaventures.com。

About PTX Capital

关于PTX资本

PTX Capital is a Baltimore-based private investment firm that backs exceptional entrepreneurs in healthcare and the life sciences. The firm invests in early-stage companies developing software, technology, and services that drive better patient outcomes, enable system-wide integration, and advance the frontiers of precision medicine.

PTX Capital 是一家位于巴尔的摩的私人投资公司，致力于支持医疗保健和生命科学领域的杰出创业者。该公司投资于开发软件、技术和相关服务的早期公司，这些公司能够改善患者治疗效果、实现全系统整合，并推动精准医学的前沿发展。

PTX works side-by-side with founding teams through the scale-up journey in order to build enduring businesses that transform care and improve health at scale..

PTX与创始团队并肩合作，贯穿规模化旅程，旨在打造能够变革医疗、大规模改善健康的持久企业。

Contact:

联系人：

Media Contact:

媒体联系人:

Josie Zohny

乔茜·佐尼

Supreme Group

最高集团

josie@clarityqst.com

乔西@清晰量子计算公司.com

917-742-3777

917-742-3777